PDFs by language
Our 24/7 cancer helpline provides support for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
At our National Cancer Information Center trained Cancer Information Specialists can answer questions 24 hours a day, every day of the year to empower you with accurate, up-to-date information to help you make educated health decisions. We connect patients, caregivers, and family members with valuable services and resources.
Or ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Important research into thyroid cancer is being done right now in many university hospitals, medical centers, and other institutions around the country. Each year, scientists find out more about what causes the disease, how to prevent it, and how to improve treatment. In past years, for example, evidence has grown showing the benefits of combining surgery with radioactive iodine therapy and thyroid hormone therapy. The results include higher cure rates, lower recurrence rates, and longer survival.
The discovery of the genetic causes of familial (inherited) medullary thyroid cancer now makes it possible to identify family members carrying the abnormal RET gene and to remove the thyroid to prevent cancer from developing there.
Understanding the abnormal genes that cause sporadic (not inherited) thyroid cancer has led to better treatments as well. In fact, treatments that target some of these gene changes are already being used, and more are being developed (see below).
Most thyroid cancers can be treated successfully. But advanced cancers can be hard to treat, especially if they do not respond to radioactive iodine (RAI) therapy. Doctors and researchers are looking for new ways to treat thyroid cancer that are more effective and lead to fewer side effects.
Doctors are looking for better ways to see which cancers are likely to come back after surgery. Patients with these cancers may be helped by getting RAI therapy after surgery. Recent studies have shown that patients with very low thyroglobulin levels 3 months after surgery have a very low risk of recurrence even without RAI. More research in this area is still needed.
Researchers are also looking for ways to make RAI effective against more thyroid cancers. For example, in some thyroid cancers, the cells have changes in the BRAF gene, which may make them less likely to respond to RAI therapy. Researchers are studying whether new drugs that target the BRAF pathway can be used to make thyroid cancer cells more likely to take up radioactive iodine. These types of drugs might be useful for people who have advanced cancer that is no longer responding to RAI therapy.
In general, thyroid cancers do not respond well to chemotherapy. But exciting data are emerging about some newer targeted drugs. Unlike standard chemotherapy drugs, which work by attacking rapidly growing cells (including cancer cells), these drugs attack specific targets on cancer cells. Targeted drugs may work in some cases when standard chemotherapy drugs do not, and they often have different side effects.
Kinase inhibitors: A class of targeted drugs known as kinase inhibitors may help treat thyroid cancer cells with mutations in certain genes, such as BRAF and RET/PTC. Many of these drugs also affect tumor blood vessel growth.
In many papillary thyroid cancers, the cells have changes in the BRAF gene, which helps them grow. Drugs that target cells with BRAF gene changes, such as vemurafenib (Zelboraf), dabrafenib (Tafinlar), and selumetinib, are now being studied in thyroid cancers with this gene change.
In one study, giving selumetinib to patients with thyroid cancers that had stopped responding to radioactive iodine (RAI) treatment helped make some patients’ tumors respond to treatment with RAI again. It helped patients not only with BRAF mutations, but also with mutations in a different gene called NRAS.
Other kinase inhibitors that have shown early promise against thyroid cancer in clinical trials include sunitinib (Sutent), pazopanib (Votrient), and axitinib (Inlyta).
Some of these other drugs, such as sunitinib, sorafenib, and pazopanib, are already approved to treat other types of cancer, and might be useful against MTC and differentiated thyroid cancers if other treatments are no longer working.
Anti-angiogenesis drugs: As tumors grow, they need a larger blood supply to get enough nutrients. They get it by forming new blood vessels (a process called angiogenesis). Anti-angiogenesis drugs work by disrupting these new blood vessels. Some of the drugs listed above, such as axitinib, sunitinib, and sorafenib, have anti-angiogenic properties.
Another anti-angiogenesis drug being studied for use against thyroid cancer is bevacizumab (Avastin).
Other targeted drugs: The combination of the chemotherapy drug paclitaxel (Taxol) with the targeted drug efatutazone could be helpful in patients with anaplastic thyroid cancer. Efatutazone targets a receptor called PPAR-gamma.
The chance of being diagnosed with thyroid cancer has risen rapidly in the US in recent years. Much of this rise appears to be the result of the increased use of thyroid ultrasound, which can detect small thyroid nodules that might not otherwise have been found in the past.
Recent international studies have suggested that some of these newly found, very small thyroid cancers (known as micro-papillary thyroid cancers) may not need to be treated right away but instead can be safely watched. Ongoing clinical trials in the US are now looking at this same approach.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol. 2010;11:962−972.
Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16:5260−5268.
Cohen E, Rosen L, Vokes E et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol. 2008;26:4708−4713.
Fagin JA. Challenging dogma in thyroid cancer molecular genetics — role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab. 2004;89:4280−4284.
Gupta-Abramson V, Troxel A, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008:26:4714−4719.
Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013 Feb 14;368(7):623-32.
Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675−1684.
Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, Wasman J, Dowlati A, Remick SC. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013 May;23(5):600-4. Epub 2013 Apr 18.
Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol. 2012 Nov;167(5):643-50. Epub 2012 Aug 23.
Smallridge RC, Copland JA, Brose MS, et al. Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400. Epub 2013 Apr 15.
Last Revised: March 14, 2019
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.